These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30806569)

  • 61. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India.
    Chugh Y; Dhiman RK; Premkumar M; Prinja S; Singh Grover G; Bahuguna P
    PLoS One; 2019; 14(8):e0221769. PubMed ID: 31465503
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Costs and quality of life of multiple sclerosis in the United Kingdom.
    Kobelt G; Berg J; Lindgren P; Kerrigan J; Russell N; Nixon R
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S96-104. PubMed ID: 17310341
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.
    Mauskopf J; Brogan AJ; Talbird SE; Martin S
    AIDS; 2012 Jan; 26(3):355-64. PubMed ID: 22089378
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Counting the costs of overweight and obesity: modeling clinical and cost outcomes.
    Tucker DM; Palmer AJ; Valentine WJ; Roze S; Ray JA
    Curr Med Res Opin; 2006 Mar; 22(3):575-86. PubMed ID: 16574040
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men.
    Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Welton ML; Palefsky JM
    JAMA; 1999 May; 281(19):1822-9. PubMed ID: 10340370
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The lifetime burden following stroke: Long term impact of stroke on survival and quality of life.
    Cheon S; Li CY; Jeng JS; Wang JD; Ku LE
    Int J Stroke; 2023 Aug; 18(7):795-803. PubMed ID: 36912208
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029.
    Marquina C; Talic S; Vargas-Torres S; Petrova M; Abushanab D; Owen A; Lybrand S; Thomson D; Liew D; Zomer E; Ademi Z
    Eur J Prev Cardiol; 2022 May; 29(8):1212-1219. PubMed ID: 33686414
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients.
    Tew M; Clarke P; Thursky K; Dalziel K
    Pharmacoeconomics; 2019 Jul; 37(7):931-941. PubMed ID: 30864067
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts.
    Amankwah N; Marrie RA; Bancej C; Garner R; Manuel DG; Wall R; Finès P; Bernier J; Tu K; Reimer K
    Health Promot Chronic Dis Prev Can; 2017 Feb; 37(2):37-48. PubMed ID: 28273039
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Costs and quality of life of multiple sclerosis in Spain.
    Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
    [TBL] [Abstract][Full Text] [Related]  

  • 74. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.
    Palmer AJ; Roze S; Valentine WJ; Minshall ME; Lammert M; Oglesby A; Hayes C; Spinas GA
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S59-66. PubMed ID: 15324517
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study.
    Palmer JL; Goodall G; Nielsen S; Kotchie RW; Valentine WJ; Palmer AJ; Roze S
    Curr Med Res Opin; 2008 May; 24(5):1417-28. PubMed ID: 18400145
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost-Effectiveness of Surgical and Nonsurgical Treatments for Unicompartmental Knee Arthritis: A Markov Model.
    Kazarian GS; Lonner JH; Maltenfort MG; Ghomrawi HMK; Chen AF
    J Bone Joint Surg Am; 2018 Oct; 100(19):1653-1660. PubMed ID: 30277995
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Costs and quality of life of multiple sclerosis in Germany.
    Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men.
    Goldie SJ; Kuntz KM; Weinstein MC; Freedberg KA; Palefsky JM
    Am J Med; 2000 Jun; 108(8):634-41. PubMed ID: 10856411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.